More on BHVN
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $15.76 |
|
|||
| Open | $15.89 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $16.51 | ||||
| Day Low | $15.60 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 3,530,661 | ||||
- Biohaven completes enrollment in focal epilepsy drug trial
- Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator
- Biohaven Pharma (BHVN) call put ratio 7.5 calls to 1 put as share price down 4.7%
- BofA cuts ratings on four biopharma stocks over valuation and catalyst concerns
- Biohaven starts Phase 3 trial of BHV-1300 for Graves' disease
- Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease
- BofA Securities Downgrades Biohaven Pharma (BHVN) to Underperform
- Biohaven Pharma (BHVN) PT Raised to $20 at Deutsche Bank
- Increasing unusual option volume: BHVN DOMO CLPT OIH CVLT PEGA OTLK VT
- Biohaven begins first human trial of brain-penetrant drug BHV-8100
Entities mentioned with BHVN
- FDA | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- PDUFA | View Related Stories »
- JPMorgan | View Related Stories »
- Show More...
